Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors
Source: Motley Fool
2026-03-05 16:25:00 ET
A surprising obesity trial result has shaken confidence in Novo Nordisk (NYSE: NVO) and sharpened the spotlight on Eli Lilly (NYSE: LLY) in this fiercely competitive GLP?1 race. Watch the video below to see what it could mean for investors.
*This video was published on Feb.24, 2026.
Eli Lilly and Company
NASDAQ: LLY
LLY Trading
-0.71% G/L:
$998.54 Last:
627,063 Volume:
$1000.03 Open:
LLY Latest News
LLY Stock Data
$977,526,804,738
935,929,919
9.81%
2658
N/A
Pharmaceuticals
Healthcare
US
Indianapolis
